Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T14677 | BMS-690514 | 859853-30-8 | 98% |
|
BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively. | ||||
T78253 | Faricimab | 1607793-29-2 | 98% |
Faricimab
|
Faricimab, a bispecific antibody, simultaneously targets angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), and is utilized in research on diabeti... | ||||
T78759 | VEGFR2-IN-4 | 98% |
|
|
VEGFR2-IN-4 (compound 25) is a potent, selective inhibitor of the VEGFR2 kinase, exhibiting a GI50 of 0.7 nM and demonstrating anti-angiogenic effects. It is uti... | ||||
T78792 | Multi-kinase-IN-4 | 98% |
|
|
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18... | ||||
T78819 | VEGFR-2-IN-33 | 98% |
|
|
VEGFR-2-IN-33 (Compound 4d), a potent VEGFR inhibitor with an IC50 value of 61.04 nM, demonstrates significant inhibition of HepG2 cell proliferation, achieving ... | ||||
T78845 | FGFR1/VEGFR2-IN-1 | 98% |
|
|
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1]. | ||||
T79009 | VEGFR2-IN-3 | 417717-09-0 | 98% |
|
VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1]. | ||||
T79400 | VEGFR-2-IN-35 | 98% |
|
|
VEGFR-2-IN-35 (compound 7) is a potent inhibitor of VEGFR-2, exhibiting an IC50 of 37 nM. Additionally, it demonstrates inhibitory activity against MCF-7 and HCT... | ||||
T79403 | VEGFR-2-IN-36 | 98% |
|
|
VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstrated antica... | ||||
T79494 | VEGFR-2-IN-31 | 98% |
|
|
VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase and in... | ||||
T79495 | VEGFR-2-IN-32 | 98% |
|
|
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2, exhibiting an inhibitory concentration (IC 50) of 8.93 nM, and demonstrates cytotoxic activity towards PC-3 c... | ||||
T79587 | HCA/VEGFR-2-IN-2 | 98% |
|
|
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII and t... | ||||
T79588 | HCA/VEGFR-2-IN-3 | 98% |
|
|
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. This compound ... | ||||
T79591 | HCA/VEGFR-2-IN-4 | 98% |
|
|
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/X... | ||||
T80152 | Protein LMWP | 121052-30-0 | 98% |
|
Protein LMWP, a cell-penetrating peptide, exhibits inhibitory activity against vascular endothelial growth factor (VEGF), and is utilized in cancer research for ... | ||||
T80287 | KLTWQELYQLKYKGI | 917760-16-8 | 98% |
|
KLTWQELYQLKYKGI (QK) is a VEGF-mimicking peptide that competes with VEGF by binding to its receptors. It facilitates the healing of gastric ulcers in rodents thr... | ||||
T80579 | Suvemcitug | 1610010-57-5 | 98% |
Suvemcitug
|
Suvemcitug, an IgG1κ antibody, specifically targets vascular endothelial growth factor (VEGF) and is derived from the African hare (Oryctolagus cuniculus) [1]. | ||||
T80593 | Brolucizumab | 1531589-13-5 | 98% |
Brolucizumab
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2]. | ||||
T80595 | Conbercept | 1227158-72-6 | 98% |
Conbercept
|
Conbercept (KH902) is a fusion protein comprising the second immunoglobulin C-like domain of FLT1 and the third and fourth immunoglobulin C-like domains of KDR, ... | ||||
T80872 | VEGFR-2-IN-37 | 298207-77-9 | 98% |
|
VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM. It is also identified as a p... |